Telomir Pharmaceuticals, Inc. (TELO) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held on September 11, 2026. The record date for the meeting was July 21, 2026. As of the record date, 68,774,954 shares of common stock were outstanding. The company is incorporated in Florida and trades on The Nasdaq Stock Market LLC under the symbol TELO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Three proposals were submitted to stockholders, and all were approved. A total of 47,129,480 shares were represented and voted, constituting approximately 68.53% of outstanding shares.
- Proposal 1 (Election of Directors): Erez Aminov, Matthew Whalen, Edward MacPherson, and Matthew Del Giudice, M.D. were elected as directors.
- Erez Aminov: 43,363,662 votes for; 93,927 votes withheld.
- Matthew Pratt Whalen: 43,365,060 votes for; 92,529 votes withheld.
- Edward MacPherson: 41,779,035 votes for; 1,678,554 votes withheld.
- Matthew Del Giudice, M.D.: 41,238,011 votes for; 2,219,578 votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders approved the appointment of Salberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 46,998,583
- Votes Against: 69,548
- Votes Abstained: 61,349
- Proposal 3 (Adjournment): Stockholders approved the adjournment of the meeting if necessary to solicit additional proxies.
- Votes For: 44,841,042
- Votes Against: 2,271,263
- Votes Abstained: 17,175
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the full text of the definitive proxy statement filed on July 28, 2026, for detailed biographies of the elected directors and the rationale for the auditor appointment.
- Confirm the specific terms of engagement with Salberg & Company, P.A. for the 2026 fiscal year.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.
- Note the significant number of broker non-votes (3,671,891) on the director election proposals, indicating shares held by brokers that were not voted on these matters.